GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Soleno Therapeutics
Soleno Therapeutics is a biotech company focused on treating rare genetic diseases. Its stock price is highly volatile and depends on clinical trial results and regulatory decisions regarding its lead drug.
Share prices of companies in the market segment - Pharma metabolism
Soleno is a biotech company focused on treating rare diseases. We classify it in the pharmaceuticals (metabolism) sector, and the chart below reflects general trends and investor sentiment in this biotech sector.
Broad Market Index - GURU.Markets
Soleno Therapeutics is a biopharmaceutical company developing treatments for rare genetic diseases, particularly Prader-Willi syndrome. Its focus on orphan diseases makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Soleno compares to it.
Change in the price of a company, segment, and market as a whole per day
SLNO - Daily change in the company's share price Soleno Therapeutics
Shares of Soleno Therapeutics, a company focused on rare diseases, are experiencing extreme volatility. Change_co measures the market's reaction to news about clinical trials and regulatory decisions. This metric is a critical component of System.GURU.Markets' formulas that assess binary risks in biotech.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Soleno Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with SLNO, which focuses on rare diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Soleno Therapeutics is a biopharmaceutical company developing drugs to treat rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Soleno's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Soleno Therapeutics
Soleno is a biotech company specializing in the treatment of metabolic diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Soleno Therapeutics, Inc. is a late-stage biotech company developing a drug to treat a rare genetic disease. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Soleno Therapeutics is a biotech company whose future depends on the success of its drug for the treatment of a rare genetic disease. Its stock price is completely disconnected from economic cycles. The chart reflects binary events from the scientific world: news about clinical trials and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Soleno Therapeutics
Soleno, a biopharmaceutical company, has a speculative market cap. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials and interactions with the FDA regarding its drug for treating a rare genetic disease, which determine its entire future value.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Soleno Therapeutics focuses on treating rare metabolic diseases such as Prader-Willi syndrome. The company's success depends almost entirely on clinical trial results and regulatory approval. A biotech sector performance chart will reveal investors' overall risk appetite, which is an important backdrop for assessing the prospects of this highly specialized company.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Soleno Therapeutics is a biotech company developing a drug to treat a rare genetic disorder, Prader-Willi syndrome. Its performance is completely unrelated to the market. Against the backdrop shown in the chart, Soleno shares could rise or fall on FDA news or clinical trial data. This is a binary bet on a single event.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Soleno Therapeutics
Shares of Soleno Therapeutics, a biopharmaceutical company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials for their drug for treating rare genetic syndromes. The chart below illustrates how biotech investor expectations and scientific data can cause sharp short-term fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
How unique is Soleno Therapeutics' performance in the biotech sector? This chart compares the company's weekly stock price movements with the overall sector trend. This helps us understand whether its sharp move, driven by news of a rare syndrome treatment, is a unique event or a reflection of overall investor sentiment in this volatile industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Soleno Therapeutics is a biotech company whose fate hinges on a single drug for the treatment of a rare genetic disease. This chart shows how disconnected its weekly performance is from the market. Its stock price is driven solely by FDA news and clinical trial results.
Market capitalization of the company, segment and market as a whole
SLNO - Market capitalization of the company Soleno Therapeutics
Soleno Therapeutics' price chart represents a concentrated bet on a single drug for the treatment of a rare genetic disorder, Prader-Willi syndrome. The company's market capitalization is almost entirely dependent on regulatory approval of this drug. Its dynamics reflect a binary outcome: either massive success or failure.
SLNO - Share of the company's market capitalization Soleno Therapeutics within the market segment - Pharma metabolism
Soleno Therapeutics is a biopharmaceutical company focused on treating rare diseases, particularly Prader-Willi syndrome. Its share of its sector market capitalization reflects investor expectations for its lead drug candidate. The chart shows how news about clinical trials and regulatory decisions dramatically impact its market value.
Market capitalization of the market segment - Pharma metabolism
The chart below shows the total value of biotech companies targeting rare genetic diseases. Soleno Therapeutics is focused on treating Prader-Willi syndrome. The dynamics in the chart reflect the high risks and expectations associated with drug discovery for orphan diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents the market value of hope for patients with the rare genetic disorder Prader-Willi syndrome. Soleno Therapeutics' market cap soared on positive trial data from its drug. The line illustrates how a biotechnology company targeting a single problem can create enormous value on a global scale.
Book value capitalization of the company, segment and market as a whole
SLNO - Book value capitalization of the company Soleno Therapeutics
Soleno Therapeutics' clinical-stage book value is determined by its scientific potential. The chart below reflects the financial valuation of its intellectual property for rare disease drugs and its research reserves. The dynamics demonstrate how the company is investing in advancing its core asset—science.
SLNO - Share of the company's book capitalization Soleno Therapeutics within the market segment - Pharma metabolism
For Soleno Therapeutics, a late-stage biopharmaceutical company, its tangible assets are limited to R&D facilities and offices. The chart shows its small share of physical infrastructure, which is typical for companies whose core value lies in clinical trial results and intellectual property.
Market segment balance sheet capitalization - Pharma metabolism
Soleno Therapeutics is a late-stage biotech company. Its value is created in laboratories where a drug for a rare genetic disease is being developed. This is a "light" model. The chart below illustrates the extent to which the biopharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Soleno Therapeutics' balance sheet is fully focused on developing a treatment for the rare genetic disorder Prader-Willi syndrome. The book value chart shows the resources focused on solving this complex medical problem, bringing hope to patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Soleno Therapeutics
Soleno Therapeutics is a biotech company focused on treating a rare genetic disorder, Prader-Willi syndrome. It has no tangible assets other than cash on hand. Its entire market capitalization is derived from the likelihood of approval of its single drug candidate. The graph is a pure bet on the regulatory decision.
Market to book capitalization ratio in a market segment - Pharma metabolism
Soleno Therapeutics is a biopharmaceutical company focused on treating rare diseases. The company has no revenue, and its market capitalization is based entirely on the success of its lead drug candidate. This chart demonstrates the enormous premium investors pay for hope.
Market to book capitalization ratio for the market as a whole
Soleno Therapeutics is a biopharmaceutical company developing a treatment for the rare genetic disorder Prader-Willi syndrome. The chart illustrates how the market values hope for patients and their families. The company's market capitalization is solely a bet on the successful approval and commercialization of its single lead drug.
Debts of the company, segment and market as a whole
SLNO - Company debts Soleno Therapeutics
Soleno Therapeutics is a late-stage biopharmaceutical company focused on treating rare diseases. Debt instruments at this stage can be critical for funding drug approval preparations and building commercial infrastructure, as demonstrated by the financial strategy in this chart.
Market segment debts - Pharma metabolism
Soleno Therapeutics is a biopharmaceutical company focused on treating rare diseases, particularly Prader-Willi syndrome. Financing in this sector is high-risk and typically occurs through stock sales. This chart illustrates general financial norms for the pharmaceutical sector, highlighting the specifics of companies in clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Soleno Therapeutics
Soleno Therapeutics is a biotech company focused on developing a treatment for the rare genetic disorder Prader-Willi syndrome. Currently in the clinical stage, the company has no revenue. This chart shows how it funds its expensive research using equity and possibly debt.
Market segment debt to market segment book capitalization - Pharma metabolism
Soleno Therapeutics is a biopharmaceutical company focused on treating rare diseases such as Prader-Willi syndrome. This chart compares the debt it raised to fund clinical trials to the overall market capitalization of the entire metabolic drug sector. It demonstrates the scale of its efforts to find treatments for patients with rare diagnoses.
Debt to book value of all companies in the market
Soleno Therapeutics is developing a drug for a rare disease. This chart compares the debt it incurred for research with the total book value of the entire economy. It shows how large the company's financial stakes are on the success of a single drug, relative to the overall size of the stock market that finances it.
P/E of the company, segment and market as a whole
P/E - Soleno Therapeutics
This figure for Soleno Therapeutics, a clinical-stage biopharmaceutical company, reflects investor expectations. Its value is determined not by current profits, but by the potential of its drug to treat rare genetic diseases. The chart shows how much the market believes in the successful completion of trials and regulatory approval of the drug.
P/E of the market segment - Pharma metabolism
This metric represents the average valuation for the biotech sector in which Soleno Therapeutics operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark.
P/E of the market as a whole
Soleno Therapeutics is a biopharmaceutical company focused on treating rare diseases, particularly Prader-Willi syndrome. The company is in the late stages of developing its lead drug. This risk appetite chart helps understand how investors value biotech companies close to launching their products.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Soleno Therapeutics
Soleno Therapeutics is a biopharmaceutical company developing a treatment for the rare genetic disorder Prader-Willi syndrome. This chart reflects investor expectations for the success of clinical trials and approval of its lead drug. It assesses the likelihood of the company bringing a life-saving treatment to market.
%20P%2FE%20Soleno%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Soleno-Therapeutics&v=1772675844470 "Chart of the company's future (projected) P/E Soleno Therapeutics")
Future (projected) P/E of the market segment - Pharma metabolism
Soleno Therapeutics is a late-stage biopharmaceutical company focused on treating rare diseases. Its lead candidate is designed to treat Prader-Willi syndrome, a rare genetic disorder. This chart shows overall market sentiment toward the biotech sector, helping to assess Soleno's potential in its complex and important niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772675844491 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Soleno Therapeutics is a biotech company developing a drug to treat the rare genetic disorder Prader-Willi syndrome. Its value depends almost entirely on the results of clinical trials and regulatory approval. Soleno's valuation is not tied to overall market forecasts, but rather a bet on scientific success.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772675844518 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Soleno Therapeutics
Soleno Therapeutics is a late-stage biopharmaceutical company focused on developing treatments for rare diseases, particularly Prader-Willi syndrome. The company's financial results reflect expenses on clinical trials and preparation for potential product launches. This chart shows the amount of investment directed toward addressing unmet medical needs.
Profit of companies in the market segment - Pharma metabolism
Soleno Therapeutics is a late-stage biopharmaceutical company focused on treating rare diseases, particularly Prader-Willi syndrome. This chart shows the profitability of the company's metabolic pharma segment. The company's current R&D expenses impact overall profitability, but its potential success could bring the first approved drug for this disease to market and drive growth.
Overall market profit
Soleno Therapeutics is a biopharmaceutical company developing treatments for rare diseases, particularly Prader-Willi syndrome. Its market capitalization is entirely dependent on the success of clinical trials and regulatory approvals. This chart illustrates general economic cycles, which have little impact on the underlying logic of development and the potential value of Soleno's assets.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Soleno Therapeutics
Soleno Therapeutics is a biopharmaceutical company in late-stage development of a drug for the treatment of Prader-Willi syndrome, a rare genetic disorder. This chart reflects analysts' future earnings expectations, which are based entirely on the likelihood of approval and commercial success of its lead and only drug candidate.
%20profit%20of%20the%20company%20Soleno%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Soleno-Therapeutics&v=1772675844559 "Graph of future (projected) profit of the company Soleno Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Soleno Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for rare diseases. This chart shows profitability projections for the metabolic pharmaceutical segment. It reflects investor expectations for clinical trial results and the market potential of the company's drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772675844562 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Soleno Therapeutics is a biopharmaceutical company developing a treatment for a rare genetic disorder associated with obesity. Its success depends on regulatory approval. However, the overall earnings outlook reflected here influences investor sentiment in the biotech sector. A positive market environment facilitates raising capital for the commercialization of life-saving drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772675844565 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Soleno Therapeutics
Soleno Therapeutics is a biopharmaceutical company developing drugs for rare diseases. While in the clinical stage, it may not generate revenue. P/S will be key after the product's approval and launch to assess market acceptance of its therapy and its commercial potential.
P/S market segment - Pharma metabolism
Soleno Therapeutics is a late-stage biopharmaceutical company developing a treatment for the rare genetic disorder Prader-Willi syndrome. Its valuation is based solely on the future potential of this drug. The chart reflects high market expectations for potential approval and commercial success in this niche market with an unmet medical need.
P/S of the market as a whole
Soleno Therapeutics is a biotech company focused on treating rare diseases, specifically Prader-Willi syndrome. The company has no revenue yet, and its valuation is based on the expected success of its key drug. This chart, showing the valuation of companies with actual revenue, highlights the speculative nature of clinical-stage biotech investments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Soleno Therapeutics
Soleno Therapeutics is a biotech company developing a drug to treat a rare genetic disorder, Prader-Willi syndrome. Its value is almost entirely dependent on this project. This chart represents the realized investor expectations for the approval and future commercial success of its single key drug.
%20P%2FS%20Soleno%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Soleno-Therapeutics&v=1772675844636 "The graph of the company's future (projected) P/S Soleno Therapeutics")
Future (projected) P/S of the market segment - Pharma metabolism
Soleno Therapeutics is a late-stage biopharmaceutical company specializing in the treatment of rare diseases, particularly Prader-Willi syndrome. This chart shows how the market assesses the future commercial potential of its lead drug candidate compared to other companies working in the field of metabolic disorders.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772675844650 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Soleno Therapeutics is a biopharmaceutical company developing a treatment for the rare genetic disease Prader-Willi syndrome. It's a classic biotech story, where success hinges on a single key drug. This chart shows aggregate market expectations for future revenue, and Soleno illustrates how the market views the potential of breakthrough treatments for rare diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772675844659 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Soleno Therapeutics
Soleno Therapeutics is a late-stage biopharmaceutical company specializing in developing treatments for rare diseases. Its lead candidate is designed to treat Prader-Willi syndrome. Revenue is likely not shown in this graph, as the company does not yet have commercialized products. Future revenue is dependent on the approval and launch of the drug.
Sales of companies in the market segment - Pharma metabolism
Soleno Therapeutics is a biotech company focused on treating rare diseases such as Prader-Willi syndrome. At this stage, its revenue, if any, may be derived from partnerships. This chart shows the financial flows supporting its research on the path to commercialization.
Overall market sales
Soleno Therapeutics is a late-stage biopharmaceutical company focused on treating rare diseases such as Prader-Willi syndrome. Its value and potential depend solely on clinical trial results and regulatory approval. The overall economic trends visible in this chart have no bearing on its scientific mission.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Soleno Therapeutics
Soleno Therapeutics is a biopharmaceutical company developing a treatment for the rare genetic disorder Prader-Willi syndrome. Its revenue forecast is entirely dependent on the approval and commercial launch of its lead drug. This chart reflects analysts' speculative expectations for the future success of this therapy.
%20sales%20of%20the%20company%20Soleno%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Soleno-Therapeutics&v=1772675844701 "Schedule of future (projected) sales of the company Soleno Therapeutics")
Future (projected) sales of companies in the market segment - Pharma metabolism
Soleno Therapeutics is a biopharmaceutical company developing treatments for rare diseases, particularly Prader-Willi syndrome. This chart shows projected revenue for the metabolic drugs segment. It allows one to assess the growth potential of this niche market, which is critical to the future commercial success of Soleno's developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772675844707 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Soleno Therapeutics is a biopharmaceutical company developing drugs to treat rare diseases such as Prader-Willi syndrome. Its value depends on the success of clinical trials, not economics. However, the overall market environment, reflected in the chart, is critical for attracting the investment needed to fund expensive R&D programs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772675844719 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Soleno Therapeutics
Soleno Therapeutics is a biopharmaceutical company focused on treating rare diseases. This chart reflects the company's financial performance at the critical stage of clinical trials. It does not represent profit, but rather investments in development. Future profitability is entirely dependent on the approval and commercial success of its lead drug candidate.
Market segment marginality - Pharma metabolism
Soleno Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, particularly Prader-Willi syndrome. This graph reflects the potential value of its developments. If approved, the drug's high profitability would demonstrate its value to patients and the lack of alternatives.
Market marginality as a whole
Soleno Therapeutics is a late-stage biotech company developing a drug to treat the rare genetic disorder Prader-Willi syndrome. Its future depends almost entirely on the approval of this drug. This overall market profitability curve is irrelevant to Soleno, for which there is only one binary outcome: success or failure.
Employees in the company, segment and market as a whole
Number of employees in the company Soleno Therapeutics
Soleno Therapeutics is a late-stage biopharmaceutical company focused on treating rare diseases such as Prader-Willi syndrome. Its small but growing team consists of scientists and clinical trial specialists. A rising chart is an important signal of progress in development and approaching commercialization.
Share of the company's employees Soleno Therapeutics within the market segment - Pharma metabolism
Soleno Therapeutics is a late-stage biopharmaceutical company focused on treating the rare genetic disorder Prader-Willi syndrome. This chart illustrates its narrow yet profound specialization. It demonstrates the proportion of leading endocrinologists and geneticists working on this complex medical problem that Soleno shares.
Number of employees in the market segment - Pharma metabolism
Soleno Therapeutics is a biopharmaceutical company focused on treating rare diseases, particularly Prader-Willi syndrome. This chart illustrates employment in the metabolic research sector. The growing number of scientists in this niche indicates progress in understanding rare genetic disorders and increasing investment in their treatment, an area in which Soleno strives to be a leader.
Number of employees in the market as a whole
Soleno Therapeutics is a biopharmaceutical company developing a treatment for the rare genetic disorder Prader-Willi syndrome. The growth of its small research team reflects not general economic trends, but rather progress in clinical research. It's an example of how highly specialized companies are creating hope and jobs in biotech.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Soleno Therapeutics (SLNO)
Soleno Therapeutics is a late-stage biotech company developing a drug to treat a rare genetic disease. Their entire value is based on investors' hopes for the approval and success of this single drug. This timeline would be off the charts for them, as their billion-dollar market cap is based on a very small staff of scientists and managers.
%20of%20the%20company%20Soleno%20Therapeutics%20(SLNO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Soleno-Therapeutics-SLNO&v=1772675844851 "Chart of market capitalization per employee (in thousands of dollars) of the company Soleno Therapeutics (SLNO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Soleno Therapeutics is a late-stage biotech focused on treating a rare genetic disease (Prader-Willi syndrome). Its entire market value is based on expectations for its single drug. This chart shows the industry average, demonstrating the significant premium investors are placing on the company's R&D team.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772675844855 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Soleno Therapeutics is a biopharmaceutical company focused on treating the rare genetic disease Prader-Willi syndrome. The company's entire value depends on the success of its clinical trials. This chart reflects the high expectations of investors, who view each employee-scientist as a key asset capable of changing the lives of patients.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772675844878 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Soleno Therapeutics (SLNO)
Soleno Therapeutics is a clinical-stage biotech company focused on treating rare diseases like Prader-Willi syndrome. Its business is pure R&D. This graph, in negative territory, shows the amount of investment burned through each scientist and employee during expensive clinical trials of a new drug.
%20Chart%20Soleno%20Therapeutics%20(SLNO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Soleno-Therapeutics-SLNO&v=1772675844885 "Company Profit Per Employee (in thousands of dollars) Chart Soleno Therapeutics (SLNO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Soleno Therapeutics is a clinical-stage biotech company specializing in the treatment of the rare Prader-Willi syndrome. This chart shows the benchmark for the "Biotech" sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies are burning through money on R&D (clinical trials).
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772675844899 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Soleno Therapeutics is a biopharmaceutical company developing a treatment for Prader-Willi syndrome (a rare genetic disorder that causes hunger). This is R&D for orphan diseases. This chart shows the market-average profit per employee. It helps understand how the biotech sector, focused on rare diseases, compares to the norm.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772675844920 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Soleno Therapeutics (SLNO)
Soleno Therapeutics is a clinical-stage biotech company. This graph likely shows no revenue per employee, which is typical for the industry. It illustrates the R&D investment phase. If the drug is commercially successful, this metric will demonstrate the enormous financial return on intellectual labor.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Soleno-Therapeutics-SLNO&v=1772675844939 "Sales chart per company employee Soleno Therapeutics (SLNO)")
Sales per employee in the market segment - Pharma metabolism
Soleno Therapeutics is a biotech company focused on treating rare diseases, specifically Prader-Willi syndrome. The company is in late-stage R&D. This chart shows the average revenue per employee in this segment, serving as a productivity benchmark for commercial pharmaceutical companies and context for evaluating SLNO staffing.
Sales per employee for the market as a whole
Soleno Therapeutics (SLNO) is a late-stage biotech focused on treating the rare Prader-Willi syndrome. Like other biotechs (NAMS, CGON), this metric currently only reflects R&D expenses. Investors are awaiting the FDA's decision. If approved, this graph should show one of the sharpest jumps, as revenue will rise virtually from scratch.
Short shares by company, segment and market as a whole
Shares shorted by company Soleno Therapeutics (SLNO)
Soleno Therapeutics is a biotech company focused on treating a rare genetic disorder, Prader-Willi syndrome. Their fate hinges on a single drug. This chart shows high skepticism. "Bears" are betting that the FDA will not approve their drug due to concerns about its efficacy or safety.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Soleno-Therapeutics-SLNO&v=1772675844973 "Short Shares Chart for the Company Soleno Therapeutics (SLNO)")
Shares shorted by market segment - Pharma metabolism
Soleno Therapeutics is a clinical-stage biotech company specializing in the treatment of rare diseases such as Prader-Willi syndrome. This chart highlights the pessimism in the biotech sector. The rise in short positions across the industry reflects a general reluctance on the part of investors to take risks in companies whose success hinges on a single drug and regulatory approval.
Shares shorted by the overall market
Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on treating rare metabolic diseases such as Prader-Willi syndrome. This chart measures overall market pessimism. For biotechs without profits, rising market fear is catastrophic. It means the window for raising capital for research is closing, as investors flee high-risk ventures.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Soleno Therapeutics (SLNO)
Soleno Therapeutics is a clinical-stage biotech. Its shares are highly sensitive to trial news. This chart for SLNO can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks or general investor risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Soleno-Therapeutics-SLNO&v=1772675844992 "RSI 14 indicator chart for the company's stock Soleno Therapeutics (SLNO)")
RSI 14 Market Segment - Pharma metabolism
Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on treating rare diseases. Its lead candidate is designed to treat Prader-Willi syndrome. This chart shows the overall sentiment in the rare metabolic disease biotech sector. It helps separate SLNO's performance from the general "noise" in the biotech sector.
RSI 14 for the overall market
Soleno Therapeutics is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SLNO (Soleno Therapeutics)
Soleno Therapeutics (SLNO) is a biopharmaceutical company in late-stage development of DCCR, a drug for the treatment of the rare genetic disorder Prader-Willi syndrome (PWS). This chart shows the average 12-month analyst forecast, reflecting their assessment of the likelihood of regulatory approval (FDA) and commercial potential for DCCR.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SLNO-Soleno-Therapeutics&v=1772675845041 "A chart showing analyst consensus forecasts for the expected stock price. SLNO (Soleno Therapeutics)")
The difference between the consensus estimate and the actual stock price SLNO (Soleno Therapeutics)
Soleno Therapeutics is a biotech company focused on treating rare diseases, primarily Prader-Willi syndrome. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in the success of their key drug candidate and its commercial potential.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SLNO-Soleno-Therapeutics&v=1772675845100 "A chart showing the difference between the consensus forecast and the actual stock price. SLNO (Soleno Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Soleno is a biotech company focused on a single goal: treating a rare and complex genetic disorder, Prader-Willi syndrome. This chart shows analysts' overall expectations for the entire metabolic pharma sector. It reflects whether experts believe in the commercial success of developments in the field of rare diseases.
Analysts' consensus forecast for the overall market share price
Soleno Therapeutics is a biotech company focused on treating the rare Prader-Willi syndrome. This is an R&D project. (Note: Pharma metabolism is correct.) This chart, reflecting expert expectations, represents risk appetite for them. During a downturn (pessimism), investors flee cash-burning biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Soleno Therapeutics
Soleno is a clinical-stage biotech focused on treating rare metabolic diseases, primarily Prader-Willi syndrome. This chart is a pure indicator of biotech expectations. It doesn't reflect current revenue, but rather an aggregated assessment of their clinical trial data and market confidence in the chances of approval of their lead drug.
AKIMA Market Segment Index - Pharma metabolism
Soleno Therapeutics is a single-product biotech targeting a rare genetic disorder, Prader-Willi Syndrome (PWS), which causes uncontrollable hunger. Their candidate (DCCR) has demonstrated success. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does Soleno's ultra-niche (PWS) R&D focus differentiate it from the average pharma company?
The AKIM Index for the overall market
Soleno is a clinical-stage biotech company focused on rare metabolic diseases (Prader-Willi syndrome). It's a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding companies like Soleno.
